Get started

Healthcare

Centene Corp | CNC | Long at $35.00Centene Corp NYSE:CNC is a healthcare enterprise providing programs and services to under-insured and uninsured families, commercial organizations, and military families in the U.S. through Medicaid, Medicare, Commercial, and other segments. The stock dropped almost 40% this morning due to recent challenges, such as a $1.8B reduction in 2025 risk adjustment revenue and rising Medicaid costs (leading to withdrawal of 2025 earnings guidance). However, the company has a book value near $56, debt-to-equity of 0.7x (healthy), a current P/E of 5x, and a forward P/E of 9x. It may be a few years before this stock recovers. But the price has entered my "crash" simple moving average area (currently between $32 and $36) and there is a price gap on the daily chart between $32 and $33 that will likely be closed before a move higher. Long-term, and potentially a new political administration, new life may enter this stock once again as the baby boom generation requires more healthcare services. But holding is not for the faint of heart... Thus, at $35.00, NYSE:CNC is in a personal buy zone with a likely continued dip into the low $30s or high $20s before a slow move higher (where I will be accumulating more shares). Full disclosure: I am also a position holder in the $60s and cost averaging down. Targets into 2028: $45.00 (+28.6%) $54.00 (+54.3%)
NYSE:CNCLong
by WorthlessViews
KALH Upside Potential?Looking purely off of KALV with the range that it has been in and the healthcare sector that it is a part of. IF healthcare sector will continue to rebound, this stock could potentially rebound as well back to the $13-$15 range. It is currently sitting right below the 200 day moving average and seems to be holding support there. I'm considering a stop loss just below $11 since this stock can move $0.83 a day with a trailing stop loss of 9%. I see it is valued under pressure of the VWAP that is currently at $12.20. This could be a beautiful continuation of the long trend that it has been in since January 2025 with an entry on this pullback. RSI looks like it is exhausting out with oversold conditions at 37.30. I like the inverted hammer that was placed and the fact that we have 3 days worth of support on the 200 day moving average. On the fundamentals, this company is a cash king in the fact they have more cash than debt. Market Cap 567.26M vs. Enterprise Value 420.76M and Insider ownership is key: Insider Ownership: 22.58%. All of which show that management are in charge and have a vision. As always, do your own research and due diligence. Not trading advice.
NASDAQ:KALVLong
by GlennTrading
ABCL: When biotechnology not only curesABCL: When biotechnology not only cures, but also makes your wallet happy! Hello, fellow investors and those who just like to tickle your nerves on the stock exchange! Today we have on our agenda (and on the chart) - the stock AbCellera Biologics Inc. (ABCL), which seems to have decided to prove that even at the bottom there is life, and then even throw a party with a breakthrough! As you can see, our hero ABCL has been playing ‘hide and seek with the trend line’ for a long time, showing an enviable resilience in the fall, just like your sofa after a day at work. However, if you look closely, the ‘ma/ema below price’ signalled that buyers, like secret agents, had already taken control of the situation, preparing for the decisive throw. And here it is, it's happening! The recent ‘breakout + retest’ is not just a technical term, but a real escape from the ‘bearish’ prison with a subsequent test of strength. Not only did price break through resistance, but it came back to see if it was indeed broken. It's like going out of the house, forgetting your keys, coming back in, getting them, and then going out again - only in the stock market it's a sign of strength and determination! Now that the dust has settled and the ‘1d’ trendline is behind us, our sights are set on the upside. Targets? Of course! ‘tp1-4.81’ and ‘tp2-6.00’ are not just numbers, they are potential points where we can pat ourselves on the shoulder and say, ‘I told you so!’. А ‘2,618 (6,61)’ - is for the very brave and patient who are willing to wait for the true bull dance. All in all, ABCL seems to have turned a page in its history, swapping sad ballads for upbeat dance hits. But remember, friends: the market is a capricious thing, and even the most beautiful charts can bring surprises. So, act wisely, don't forget about risks and, of course, enjoy the process! Have a good trading!
NASDAQ:ABCLLong
by TotoshkaTrades
HIMS 1D — This pattern didn’t cook for nothingOn the daily chart of Hims & Hers Health, we’re looking at a textbook cup with handle formation — not just a pattern, but a structure backed by time, volume, and classic price behavior. The base of the cup formed steadily from February to May 2025, and as soon as the curve was complete, price transitioned into a tight consolidation — the "handle" that often masks real accumulation. Right now, price is testing the resistance area. And it’s not just floating up there — it’s coming in hot: price has already broken through EMA 20/50/100/200 and SMA 50/200. That’s a full stack flip. This isn’t sideways noise — it’s a structural shift in control. Volume is starting to build as price rises, confirming that demand is real and institutional positioning likely active. We’re watching a breakout zone above the handle — and when that breaks, the structure unlocks with a clear target: $107.25, roughly a 2x move from current levels. This setup isn’t noise. It’s a long-cooked formation that’s now about to boil over. If the handle holds and price breaks through — the rest is just follow-through.
NYSE:HIMSLong
by TotoshkaTrades
12
eHealth | EHTH | Long at $4.22eHealth NASDAQ:EHTH , the largest online private health insurance marketplace, may be undervalued. The book value is listed around $19 a share and it has a debt-to-equity of 0.07x (healthy), a quick ratio of 2.5 (strong liquidity, can cover liabilities), growing revenue since 2021 (over $500M in 2024), and insiders have recently bought shares/awarded options. However, profitability is still a concern, but the company is expected to be profitable by 2026. With the US's aging population and the need for affordable healthcare coverage, eHealth *may* standout as a major insurance marketplace... but time will tell. From a technical analysis perspective, the stock price is near the bottom of its historical simple moving average. I do not doubt, however, that the stock may slip to cover the small price gap between $3.09 and $3.23 (which will be another entry point if fundamentals do not change). This stock may trade sideways for some time. But it has a 27M float and as we saw in 2014 and 2020, it can REALLY get going if buyers see the opportunity... Thus, at $4.22, NASDAQ:EHTH is in a personal buy zone with more opportunity potentially near $3 in the future. Targets: $6.00 (+42.2%) $8.00 (+89.6%)
NASDAQ:EHTHLong
by WorthlessViews
UNH : Are Bad Days Over ? (Cautious)UNH shares have moved above the 50-period moving average but are trading below the 200-period moving average. For now, since the 200-period moving average is very high, a small trade can be tried by keeping the stop-loss level a little tight. A few weak movements may pull the average down and the price may break the average. Therefore, small position sizes are ideal. NOTE : If we can maintain persistence on 376(Which will take a few days), then we will look at the other gaps. Risk/Reward Ratio : 2.39 Stop-Loss : 274.99 Take- Profit Level : 376.38 Regards.
NYSE:UNHLong
by Noldo
Regeneron Pharmaceuticals | REGN | Long at $502.28Regeneron Pharmaceuticals NASDAQ:REGN stock dropped more than 17% today due to mixed Phase 3 trial results for itepekimab, a potential COPD drug. However, the company has an extensive drug pipeline, raked in over $14 billion last year, and is currently trading at a price-to-earnings of 15x. Debt-to-equity is 0.09x (extremely healthy) and earnings are forecast to grow 7.5% per year. While 2025 is anticipated to be its "worst" earnings year, the outlook through 2028 looks like steady growth in revenue and cash flow. From a technical analysis view, the stocks entered my "crash" simple moving average zone today (currently between $466 and $502). More often than not, this area signals a bottom in the near-term, but it's not guaranteed. I wouldn't be surprised if the $450s-$460s get hit before a reversal if the market shifts negatively - which will be another entry for me. If it moves into my "major" crash zone in the $300s to close more gaps on the daily chart, I will be piling into this stock heavily (like I did with NYSE:UNH ) for a longer-term hold - of course, unless fundamentals change. I'm going to keep my target small unless there is a "major crash" and eye the closing of the nearest price gap on the daily. There is another between $883-$914... Targets: $590 (+17.5%)
NASDAQ:REGNLong
by WorthlessViews
1
Is Gene Editing's Investment Promise Within Reach?CRISPR Therapeutics stands at the vanguard of the gene editing revolution, transitioning into a commercial-stage biopharmaceutical entity following the landmark approval of CASGEVY. This first-of-its-kind gene editing treatment targets sickle cell disease and beta-thalassemia, validating the transformative potential of CRISPR-Cas9 technology and signaling the dawn of a new medical era. CASGEVY's market entry provides critical proof of concept, paving the way for broader gene editing applications in treating genetic disorders. Despite this scientific triumph, CASGEVY's commercial launch faces immediate hurdles, primarily its high cost and complex administration, contributing to slow initial sales. While development partner Vertex Pharmaceuticals reports the revenue, CRISPR receives a profit share. The company currently operates at a loss, with operating expenses significantly exceeding revenue, primarily from grants. However, a robust cash reserve provides financial stability as CRISPR pursues an ambitious pipeline targeting widespread diseases like cancer, diabetes, and cardiovascular conditions, alongside its commercial efforts with CASGEVY. The intellectual property landscape remains dynamic, marked by ongoing patent disputes over the foundational CRISPR-Cas9 technology, which could influence future licensing and competition. Simultaneously, CRISPR Therapeutics contributes to advancements in personalized medicine and delivery systems. A notable achievement includes the rapid development and delivery of a personalized mRNA-based CRISPR therapy for a rare metabolic disorder using lipid nanoparticles, demonstrating a potential model for swift, patient-specific treatments and highlighting the crucial role of advanced delivery technologies in expanding gene editing's therapeutic reach. For investors, CRISPR Therapeutics presents a high-risk, high-reward opportunity. The stock has experienced volatility, reflecting current unprofitability and market conditions. Yet, strong institutional ownership and optimistic analyst ratings underscore confidence in the long-term potential. The company's deep pipeline and foundational technology position it for significant future growth if clinical programs succeed and commercial adoption of its therapies expands, suggesting that for those with a long-term perspective, the promise of gene editing may indeed be within reach.
NASDAQ:CRSPLong
by UDIS_View
2
OSCR (Long) - Impressive growth, with low but improving marginsMy last healthcare idea, which is also my most recent, has gone spectacularly wrong after the stock fell precipitously on news which I was not able to source despite my extensive efforts. So, what else to do then than to jump on another attractive healthcare idea - NYSE:OSCR Fundamentals The underlying growth of NYSE:OSCR can only be described as impressive, with the firm growing by more than 40% every quarter (y-o-y) ever since it has gone public back in 2021 (despite already reaching over 10b in annual sales) - I left the numbers in the chart for a reference The reason why its valuation is so low (0.4 P/S) compared to its peers is mainly the razor-thin margins , with EBITDA margins hovering only around 2% - but this is coming from a negative territory and most importantly, continues improving. The firm just reported another stellar earnings and from the public discourse, its insurance solutions seem to steaming through the market and gaining market share The main risk, which is pretty significant if realized, is political, and tied to the ACA subsidies - for a great article you can read about it here However, for someone who plans to hold for the next 3-6 months (like myself), this shouldn't be an issue Technicals As mentioned, the firm recently released stellar earnings which propelled the price >20% higher. After a little consolidation, the price seems to have held its ground and is now poised to go higher The stock price also broke out from a base as depicted on the chart, though I have to admit, it does not have the degree of accumulation I would prefer but the overall setup still looks very attractive Momentum indicators like Stochastic and MACD are all entering positive territory, meaning we are likely only entering the upside potential Trade I entered the trade right after the breakout as I had been eyeing the stock for some time. The next few days confirmed the breakout and the stock is now seemingly heading higher, providing another good entry point The low of where the stock price now consolidated also represents a great stop loss point (marked by the red line on the graph) No price targets as I am just looking to watch how the price action evolves over next weeks, but breaking the previous local high would be a good point for potentially adding Follow me for more analysis & Feel free to ask any questions you have, I am happy to help If you like my content, Please leave a like, comment or a donation , it motivates me to keep producing ideas, thank you :)
NYSE:OSCRLong
by jurajholik
UnitedHealth Group | UNH | Long at $323.00UnitedHealth Group NYSE:UNH currently has a P/E near 15x, steady rising revenue (2024 = $400+ billion), EPS of 6.24x, dividend of 2.2%, and earnings are forecast to grow by 10.8% per year. The stock, however, has plummeted recently due to negative news, rising healthcare costs, CEO changes, and suspension of 2025 outlook. Every company has bumps, but I view solid companies like NYSE:UNH as pure opportunities for long-term investment - especially with America's aging population. From a technical analysis perspective, the stock price has entered my "crash" simple moving average zone (which currently extends down near $307.00). Personally, this is the zone I am starting a position due to the odds of a future bounce from here. However, I am very aware that there is an open price gap near $265.00 that may get filled this year or early next. I could see a bounce in my crash zone to bring in the bulls and then a drop to that level to heighten the fear. That is another area I plan to grab more shares and build a strong position. But, in case it doesn't extend that low, I have started a position at $223.00, with future investments near $307.00 and below. I doubt this will be a quick turnaround stock - patience is where money is made. Targets (into 2028): $375.00 $475.00 $580.00
NYSE:UNHLong
by WorthlessViews
AI in Biotech: The Future of Cancer Therapy?Lantern Pharma Inc. is making waves in the biotech sector, leveraging its proprietary RADR® AI platform to accelerate the development of targeted cancer therapies. The company recently achieved significant milestones, including FDA clearance for a Phase 1b/2 trial of LP-184 in a difficult-to-treat non-small cell lung cancer (NSCLC) subset. This patient population, characterized by specific genetic mutations and poor response to existing treatments, represents a substantial unmet medical need and a multi-billion-dollar market opportunity. LP-184's mechanism, which selectively targets cancer cells overexpressing the PTGR1 enzyme, offers a precision approach aimed at improving efficacy while reducing toxicity. LP-184's potential extends beyond NSCLC, having received multiple FDA Fast Track Designations for aggressive cancers like Triple-Negative Breast Cancer (TNBC) and Glioblastoma. Preclinical data support its activity in these areas, including synergy with other therapies and favorable properties like brain penetrance for CNS cancers. Furthermore, Lantern Pharma has demonstrated a commitment to rare pediatric cancers, securing Rare Pediatric Disease Designations for LP-184 in MRT, RMS, and hepatoblastoma, which could also yield valuable priority review vouchers. The company's financial position, marked by strong liquidity according to InvestingPro data, supports its ongoing investment in R&D and its AI-driven pipeline. While reporting a net loss reflecting these investments, Lantern Pharma anticipates key data readouts in 2025 and actively seeks further funding. Analysts view the stock as potentially undervalued, with price targets suggesting future growth. Lantern Pharma's strategy of combining advanced AI with a deep understanding of cancer biology positions it to address high-need patient populations and potentially transform oncology drug development.
NASDAQ:LTRNLong
by UDIS_View
ImmunityBio: Catalyst for a New Era?ImmunityBio, Inc. is rapidly emerging as a significant force in the biotechnology sector, propelled by the success and expanding potential of its lead immunotherapy asset, ANKTIVA® (nogapendekin alfa inbakicept-pmln). The company achieved a pivotal milestone with the FDA approval of ANKTIVA in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. This approval addresses a critical need and leverages ANKTIVA's unique mechanism as a first-in-class IL-15 agonist, designed to activate key immune cells and induce durable responses. Building on this success, ImmunityBio is actively pursuing global market access, submitting applications to the EMA and MHRA for potential approval in Europe and the UK by 2026. Beyond regulatory progress, ImmunityBio proactively tackles challenges in patient care, notably addressing the U.S. shortage of TICE® BCG. Through an FDA-authorized Expanded Access Program, the company supplies recombinant BCG (rBCG), providing a vital alternative source and expanding treatment access, particularly in underserved areas. This initiative supports patients and establishes a new market channel for ImmunityBio's therapies. Commercially, ANKTIVA's U.S. launch gains momentum, facilitated by a permanent J-code that simplifies billing and broadens insurance coverage, reaching over 240 million lives. ImmunityBio's strategic vision extends to other major cancer types. The company is advancing ANKTIVA's potential in non-small cell lung cancer (NSCLC) through a confirmatory Phase 3 trial with BeiGene. This collaboration follows promising Phase 2 data demonstrating ANKTIVA's ability to rescue checkpoint inhibitor activity in patients who have progressed on prior therapies, showing prolonged overall survival. This highlights ANKTIVA's broader potential as a foundational cytokine therapy capable of addressing lymphopenia and restoring immune function across various tumors. ImmunityBio's recent financial performance reflects this clinical and commercial traction, marked by a significant revenue increase driven by ANKTIVA sales and positive investor sentiment.
NASDAQ:IBRXLong
by UDIS_View
Can Lilly Redefine Weight Loss Market Leadership?Eli Lilly is rapidly emerging as a dominant force in the burgeoning weight loss drug market, presenting a significant challenge to incumbent leader Novo Nordisk. Lilly has demonstrated remarkable commercial success despite its key therapy, Zepbound (tirzepatide), entering the market well after Novo Nordisk's Wegovy (semaglutide). Zepbound's substantial revenue in 2024 underscores its rapid adoption and strong competitive standing, leading market analysts to project Eli Lilly's obesity drug sales will surpass Novo Nordisk's within the next few years. This swift ascent highlights the impact of a highly effective product in a market with immense unmet demand. The success of Eli Lilly's tirzepatide, the active ingredient in both Zepbound and the diabetes treatment Mounjaro, stems from its dual mechanism targeting GLP-1 and GIP receptors, offering potentially enhanced clinical benefits. The company's market position was further solidified by a recent U.S. federal court ruling that upheld the FDA's decision to remove tirzepatide from the drug shortage list. This legal victory effectively halts compounding pharmacies from producing unauthorized, cheaper versions of Zepbound and Mounjaro, thereby protecting Lilly's market exclusivity and ensuring the integrity of the supply chain for the approved product. Looking ahead, Eli Lilly's pipeline includes the promising oral GLP-1 receptor agonist, orforglipron. Positive Phase 3 trial results indicate its potential as a convenient, non-injectable alternative with comparable efficacy to existing therapies. As a small molecule, orforglipron offers potential advantages in manufacturing scalability and cost, which could significantly expand access globally if approved. Eli Lilly is actively increasing its manufacturing capacity to meet anticipated demand for its incretin therapies, positioning itself to capitalize on the vast and growing global market for weight management solutions.
NYSE:LLYLong
by UDIS_View
GE Healthcare Technology | GEHC | Long at $62.25GE Healthcare Technology $NASDAQ:GEHC. An aging and unhealthy population will only create an increased need for healthcare imaging services. Add AI to the diagnostic mix, and imaging will be imperative for routine health maintenance and screening. With a P/E of 15x, debt-to equity of 1x, earnings forecast growth of 8.36% per year, and bullish analyst ratings, this could be a good value play for the patient. Thus, at $62.25, NASDAQ:GEHC is in a personal buy zone. Further drops are possible if trade wars make imaging materials/technology difficult to obtain, but that general statement applies to the whole market at this time... Targets: $70.00 $78.00
NASDAQ:GEHCLong
by WorthlessViews
Acadia Healthcare Company | ACHC | Long at $21.98Acadia Healthcare's NASDAQ:ACHC stock has fallen nearly -76% in a year, primarily due to weak 2024 results, missed revenue and EPS expectations, and a soft 2025 revenue guidance. Ongoing federal investigations into billing practices and lawsuits have further eroded investor confidence. However, it is currently trading at a price-to-earnings ratio of 7.42x and earnings are forecast to grow 7.07% per year. The profitable company is trading at a good value compared to other healthcare companies. Debt-to-equity is relatively low (0.64x), but legal risks (DOJ probe, lawsuits) strain margins. The stock has entered my "major crash" simple moving average territory and there is a lot of downward / selling pressure. But, more often than not, this area (which... I caution... still extends down near $16) can often signal a temporary or longer-term bottom. Personally, this is a buy area ($16-$21) even if it turns into a short-term bounce in 2025. But I believe the overall market moves in the S&P 500, etc. will guide this stock more than anything at this point (unless more bad news about the company emerges). One thing to note is that there are open price gaps on the daily chart near $17, $10, and $8. These gaps, which often (but not always) get closed in the lifetime of a stock, are a potential signal for further declines - at least at some point. There could be a drop near $16, then a $10-$20 bullish price increase after that, followed by more declines (trapping investors). Time will tell, but NASDAQ:ACHC is currently attractively valued. From a technical analysis standpoint, it is in a personal "buy zone", even if purely for a swing trade. Targets: $27.00 $33.00 $39.00
NASDAQ:ACHCLong
by WorthlessViews
AGL (Long) - Bucking the overall market trendAs I was scrolling through many many charts, I realized its very difficult these days to find a stock that trades on its own accord, without copying the (very volatile) path of the overall market. But I managed to find one which showed almost no correlation to the recent frenzy - NYSE:AGL Fundamentals The underlying fundamentals of NYSE:AGL are difficul t to say the least, though getting better - hence the recent bump in the share price on the back of a few upgrades from analysts With a P/S of 0.4 we can confidently say the valuation is low, but we can't really blame the investors for taking the share price down - despite an amazing growth rate (from 4.3bn in 2023 to 6bn in 2024), the firm is unable to keep its costs and cash position in check With 6bn in revenue , the firm wasn't able to turn a positive gross profit(!) So, I wouldn't look at it yet as a long-term play, though if the firm can put its finances in order, it could be a large player in the definitely-not-getting-smaller space of senior healthcare But the short-term momentum is intruiging Technicals First thing to note is that fascinating bifurcation from the broader market (see the relative strength indicator on the weekly); NYSE:AGL was nicely treading 6% higher today while AMEX:SPY was bleeding 7% - I appreciate stocks like that during these volatile days Plus,it has momentum - a couple of upgrade sent the stock surging and there is a gap to fill, which I would like to take advantage off Other than that, it doesn't really scream buy, so I am not going to sell it as a high-conviction play (no usual accumulation patterns :/) - I am currently looking at it as a diversification play with a momentum tailwind Trade I bought it on the recent pop higher and plan to hold until it breaks the little bottom it created after it surged (red line) I don't plan to marry the stock for longer, I will give it one chance and if it breaks, then I retreat - potential holding time is about a month , or about 5 U-turns in the US tariff policy The stock can be still entered with the same stop/loss but a slightly worse risk/reward Follow me for more analysis & Feel free to ask any questions you have, I am happy to help If you like my content, Please leave a like, comment or a donation, it motivates me to keep producing ideas, thank you :)
NYSE:AGLLong
by jurajholik
The Collaborative Edge: Pfizer's Innovation Secret? Pfizer's success in the biopharmaceutical industry hinges on its internal capabilities and a strategic embrace of external collaboration. This proactive approach, spanning diverse technological frontiers, fuels innovation across its operations. From partnering with QuantumBasel and D-Wave to optimize production planning using quantum annealing, to collaborating with XtalPi to revolutionize drug discovery through AI-powered crystal structure prediction, Pfizer demonstrates the tangible benefits of cross-industry partnerships. These initiatives showcase a commitment to exploring cutting-edge technologies to enhance efficiency and accelerate the identification of promising drug candidates, ultimately improving patient outcomes and strengthening Pfizer's competitive position. The article highlights specific examples of Pfizer's collaborative endeavors. The Pfizer Healthcare Hub in Freiburg acts as a catalyst, connecting internal needs with external innovation. The successful proof of technology in production planning using quantum annealing resulted in significant time and resource savings. Furthermore, the partnership with XtalPi has dramatically reduced the timeframe for determining the 3-D structure of potential drug molecules, enabling faster and more efficient drug screening. These collaborations exemplify Pfizer's strategic focus on leveraging specialized expertise and advanced technologies from external partners to overcome complex challenges in the pharmaceutical value chain. Beyond these specific projects, Pfizer actively engages with the broader quantum computing landscape, recognizing its transformative potential for drug design, clinical studies, and personalized medicine. Collaborations with technology giants like IBM and fellow pharmaceutical companies underscore the industry-wide interest in harnessing the power of quantum computing. While the technology is still in its early stages, Pfizer's proactive participation in this collaborative ecosystem positions it at the forefront of future healthcare breakthroughs. This commitment to synergy, from basic research to market research, underscores a fundamental belief in the power of working together to drive meaningful advancements in the pharmaceutical industry.
NYSE:PFELong
by UDIS_View
Cracks Appearing in J&J's Armor?Johnson & Johnson, a long-established leader in the global healthcare sector, confronts substantial challenges that raise significant questions about its future trajectory and stock valuation. Foremost among these is the persistent and massive litigation surrounding its talc-based baby powder. With tens of thousands of lawsuits alleging links to cancer, the company's strategy to manage this liability via bankruptcy has been repeatedly struck down by courts, most recently rejecting a $10 billion settlement proposal. This forces J&J to potentially face over 60,000 individual claims in court, introducing immense financial uncertainty and the prospect of staggering legal costs and damages. Compounding these concerns is mounting scrutiny over the company's historical and recent marketing practices. A federal judge recently imposed a $1.64 billion penalty against J&J's pharmaceutical arm for misleading marketing of HIV medications, citing a "deliberate and calculated scheme." This follows earlier multi-million dollar settlements related to alleged improper financial inducements paid to surgeons for orthopaedic implants by its DePuy subsidiary, and tax disputes in India over questionable "professional sponsorship" expenses tied to similar activities. These incidents depict recurring legal and ethical entanglements with significant financial penalties and reputational harm. Taken together, the unresolved talc litigation, substantial financial penalties from marketing violations, and persistent questions regarding ethical conduct create considerable headwinds for Johnson & Johnson. The cumulative impact of ongoing legal battles, potential future liabilities, and damage to its corporate image threatens to drain resources, divert management focus from core operations, and erode investor confidence. These converging factors present tangible risks that could exert significant downward pressure on the company's stock price moving forward.
NYSE:JNJShort
by UDIS_View
Zoetis | ZTS | Long at $156.94Zoetis NYSE:ZTS , the largest global animal health company, generated more than $9 billion in revenue in 2024 and earnings have grown 9.3% per year over the past 5 years. Free cash flow for FY2024 was over $2.2 billion. Dividend consistently raised every year for the past for years (currently 1.28%). The growth of the company isn't expected to slow any time soon, and I believe the animal health care market will grow right alongside the human health care market - if not potentially faster (people love their pets). Thus, at $156.94, NYSE:ZTS is in a personal buy zone. There may be some near-term risk with the potential for a daily price-gap close near $136.00, but I personally view that as an even better buy opportunity (unless fundamentals change). Targets $170.00 $180.00 $200.00
NYSE:ZTSLong
by WorthlessViews